Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine

被引：0
|
作者：
Huaiyu Yang
Lara Sinicropi-Yao
Sarah Chuzi
Soo Jeong Youn
Alisabet Clain
Lee Baer
Ying Chen
Patrick J McGrath
Maurizio Fava
George I Papakostas
机构：
[1] Harvard Medical School,Depression Clinical and Research Program, Massachusetts General Hospital
[2] Columbia University,Depression Evaluation Service Center, New York State Psychiatric Institute
来源：
Annals of General Psychiatry | / 9卷
关键词：
Major Depressive Disorder; Fluoxetine; Major Depressive Disorder; Hamilton Depression Rate Scale; Residual Symptom;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy
    Strawn, Jeffrey R.
    Mills, Jeffrey A.
    Croarkin, Paul E.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2019, 29 (04) : 250 - 255
  • [22] Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder
    Palmer, Emma C.
    Binns, Lindsey N.
    Carey, Heather
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (08) : 1030 - 1039
  • [23] Duloxetine:: A dual serotonin-norepinephrine reuptake inhibitor for treatment of major depressive disorder
    Kirwin, JL
    Gören, JL
    PHARMACOTHERAPY, 2005, 25 (03): : 396 - 410
  • [24] Hyponatremia associated with selective serotonin reuptake inhibitor in patients with major depressive disorder: A preliminary report
    Bahk, W-M.
    Jung, Y. -E.
    Seo, H. -J.
    Chae, J. -H.
    Jun, T. -Y.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 201 - 201
  • [25] Exploring treatment alternatives: Weekly dosing of fluoxetine for the continuation phase of major depressive disorder
    Burke, WJ
    McArthur-Miller, DA
    JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 : 38 - 42
  • [26] Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder
    Clayton, AH
    Zajecka, J
    Ferguson, JM
    Filipiak-Reisner, JK
    Brown, MT
    Schwartz, GE
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2003, 18 (03) : 151 - 156
  • [27] Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics
    Y Ji
    J M Biernacka
    S Hebbring
    Y Chai
    G D Jenkins
    A Batzler
    K A Snyder
    M S Drews
    Z Desta
    D Flockhart
    T Mushiroda
    M Kubo
    Y Nakamura
    N Kamatani
    D Schaid
    R M Weinshilboum
    D A Mrazek
    The Pharmacogenomics Journal, 2013, 13 : 456 - 463
  • [28] THE EFFECT OF SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI) TREATMENT ON MEAN PLATELET VOLUME IN MAJOR DEPRESSIVE DISORDER (MDD) PATIENTS
    Demircan, Fatih
    Gozel, Nevzat
    Kilinc, Faruk
    Yilmaz, Musa
    Donder, Emir
    Atmaca, Murad
    ACTA MEDICA MEDITERRANEA, 2016, 32 (01): : 93 - 96
  • [29] Brain Monoamine Oxidase A Binding in Major Depressive Disorder Relationship to Selective Serotonin Reuptake Inhibitor Treatment, Recovery, and Recurrence
    Meyer, Jeffrey H.
    Wilson, Alan A.
    Sagrati, Sandra
    Miler, Laura
    Rusjan, Pablo
    Bloomfield, Peter M.
    Clark, Michael
    Sacher, Julia
    Voineskos, Aristotle N.
    Houle, Sylvain
    ARCHIVES OF GENERAL PSYCHIATRY, 2009, 66 (12) : 1304 - 1312
  • [30] Modafinil combined with selective serotonin reuptake inhibitor at treatment initiation enhances the rate and degree of benefit in major depressive disorder
    Ninan, PT
    Hassman, HA
    Glass, SJ
    McManus, FC
    Sciamanna, A
    JOURNAL OF PSYCHOPHARMACOLOGY, 2004, 18 (03) : A13 - A13
12345